Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 79.5% in October

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 10,100 shares, a drop of 79.5% from the October 15th total of 49,200 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 28,000 shares, the short-interest ratio is currently 0.4 days.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Logos Global Management LP purchased a new stake in shares of Avalo Therapeutics during the second quarter valued at about $6,722,000. Ikarian Capital LLC bought a new position in shares of Avalo Therapeutics during the 1st quarter worth approximately $1,015,000. Finally, Affinity Asset Advisors LLC lifted its position in Avalo Therapeutics by 350.0% during the second quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock valued at $561,000 after acquiring an additional 35,000 shares during the last quarter. Institutional investors own 87.06% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright initiated coverage on shares of Avalo Therapeutics in a research note on Thursday, October 24th. They issued a “neutral” rating for the company.

Avalo Therapeutics Trading Up 4.6 %

NASDAQ AVTX opened at $13.40 on Thursday. The firm’s 50 day moving average price is $10.53 and its 200-day moving average price is $11.13. Avalo Therapeutics has a 52-week low of $3.95 and a 52-week high of $34.46.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Monday, August 12th. The company reported ($14.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.70) by ($7.37). As a group, research analysts expect that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.